Pipeline

The products to follow Cxbladder^® and Cxcolorectal^® into the market from Pacific Edge are for gastric cancer and melanoma:

• Gastric cancer diagnosis and prognosis: this product is in pre-clinical trials.

• Gastric cancer triage: this 2-biomarker immunoassay for delivery at point of care is currently in development.

• Melanoma diagnosis and prognosis: Pacific Edge, in collaboration with the Ludwig Institute for Cancer Research, have identified and validated a prognostic gene signature for the identification of aggressive stage II melanoma. The signature is in pre-clinical trials.

Pacific Edge's Product Pipeline